Mark Sulkowski
Experienced in Sepsis

Dr. Mark Sulkowski

Infectious Disease
Johns Hopkins Medicine
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Lutherville, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
31 Years of Experience

Experienced in Sepsis
Johns Hopkins Medicine
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Lutherville, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017). Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries.

Dr. Sulkowski is rated as an Experienced provider by MediFind in the treatment of Sepsis. His top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B.

His clinical research consists of co-authoring 287 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Sepsis.

Residency
Duke University Medical Center, Internal Medicine, 1995
Specialties
Infectious Disease
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Infectious Diseases, 1998
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Falls Concourse STE 412, Lutherville, MD 21093
Call: 410-583-2900
Other Locations
The Johns Hopkins Hospital
1717 East Monument Street, Park Building, Ground Level, Baltimore, MD 21287
Call: 410-955-1725

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
Enrollment Status: Recruiting
Publish Date: June 08, 2025
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Enrollment Status: Completed
Publish Date: November 17, 2025
Intervention Type: Other, Drug
Study Drugs: Ivermectin, Fluvoxamine, Fluticasone
Study Phase: Phase 3
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
HBV-HIV Coinfection Research Network
HBV-HIV Coinfection Research Network
Enrollment Status: Completed
Publish Date: May 16, 2023
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection
Enrollment Status: Terminated
Publish Date: July 14, 2022
Intervention Type: Drug, Other
Study Drug: PegIFN-Lambda Alpha1a
Study Phase: Phase 2
deLIVER: Direct Acting Antiviral Effects on the Liver
deLIVER: Direct Acting Antiviral Effects on the Liver
Enrollment Status: Completed
Publish Date: February 24, 2022
Intervention Type: Drug
Study Phase: Phase 4
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Enrollment Status: Unknown
Publish Date: December 13, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

287 Total Publications

Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial.
Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial.
Journal: medRxiv : the preprint server for health sciences
Published: October 01, 2025
View All 287 Publications
Similar Doctors
Elite in Sepsis
Dr. Robert L. Danner
Infectious Disease | Intensive Care Medicine
Elite in Sepsis
Dr. Robert L. Danner
Infectious Disease | Intensive Care Medicine
Critical Care Medicine Department, Nih, Building 10, Room 2c145, 
Bethesda, MD 
 (37.9 miles away)
301-496-9320
Languages Spoken:
English

Robert Danner is an Infectious Disease specialist and an Intensive Care Medicine provider in Bethesda, Maryland. Dr. Danner is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Toxic Shock Syndrome, Necrotizing Fasciitis, and Anthrax Infection.

Elite in Sepsis
Dr. Sameer S. Kadri
Intensive Care Medicine | Hospital Medicine | Infectious Disease
Elite in Sepsis
Dr. Sameer S. Kadri
Intensive Care Medicine | Hospital Medicine | Infectious Disease

Mgmc LLC

18101 Prince Philip Dr, 
Olney, MD 
 (28.8 miles away)
301-774-8881
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sameer Kadri is an Intensive Care Medicine specialist and a Hospital Medicine provider in Olney, Maryland. Dr. Kadri is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Necrotizing Fasciitis, Toxic Shock Syndrome, and Severe Acute Respiratory Syndrome (SARS). Dr. Kadri is currently accepting new patients.

Sara Cosgrove
Distinguished in Sepsis
Dr. Sara Cosgrove
Infectious Disease
Distinguished in Sepsis
Dr. Sara Cosgrove
Infectious Disease

The Johns Hopkins Hospital

1800 Orleans Street, 
Baltimore, MD 
 (4.3 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances

Dr. Cosgrove is a Professor of Medicine in the Division of Infectious Disease (ID) at Johns Hopkins University School of Medicine and has a joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Research for the ID Fellowship Program and PI of the T32 training grant that supports ID fellow training. She serves as the Director of the Department of Antimicrobial Stewardship and an Associate Hospital Epidemiologist at The Johns Hopkins Hospital. Dr. Cosgrove’s research interests include the epidemiology and outcomes of antimicrobial resistance, the development of tools and programs to promote the rational use of antimicrobials, the prevention of hospital-acquired infections, and the epidemiology and management of S. aureus bacteremia. Early in her career, she recognized the critical need to study antimicrobial stewardship strategies and has led a series of outcomes studies over the past 20 years that have defined the practice of antimicrobial stewardship in the United States. Her recent research focuses on strategies for implementation of antimicrobial stewardship activities across all healthcare settings via a large, multi-center project including hospitals, long-term care facilities and ambulatory practices funded by the Agency for Healthcare Research and Quality, and approaches to improve how antibiotics are given via a randomized trial to compare intravenous and oral therapy for Gram negative bacteremia funded by PCORI. She is the PI of the Johns Hopkins Prevention Epicenter, a Centers for Disease Control and Prevention-funded program that integrates antimicrobial stewardship, healthcare epidemiology, human factors engineering, data science, and implementation science to address knowledge gaps and develop strategies to optimize patient safety by preventing transmission of pathogens and improving antibiotic use in diverse healthcare settings and patient populations. She is a past voting member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She is a Past President of the Society for Healthcare Epidemiology’s Board of Directors. Dr. Cosgrove received her undergraduate degree from Columbia College, her medical degree from Baylor College of Medicine, and her master of science degree in epidemiology from Harvard School of Public Health. She completed her postgraduate training in internal medicine at The Johns Hopkins Hospital and underwent subsequent training in ID at Beth Israel Deaconess Medical Center. Dr. Cosgrove is rated as an Advanced provider by MediFind in the treatment of Sepsis. Her top areas of expertise are Sepsis, Methicillin-Resistant Staphylococcus Aureus (MRSA), Pneumonia, and Pseudomonas Stutzeri Infections.

VIEW MORE SEPSIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sulkowski's expertise for a condition
ConditionClose
  • Elite
  • Hepatitis
    Dr. Sulkowski is
    Elite
    . Learn about Hepatitis.
    See more Hepatitis experts
  • Hepatitis C
    Dr. Sulkowski is
    Elite
    . Learn about Hepatitis C.
    See more Hepatitis C experts
  • HIV/AIDS
    Dr. Sulkowski is
    Elite
    . Learn about HIV/AIDS.
    See more HIV/AIDS experts
  • Distinguished
  • Hepatitis B
    Dr. Sulkowski is
    Distinguished
    . Learn about Hepatitis B.
    See more Hepatitis B experts
    • Experienced
    • AIDS Dementia Complex
      Dr. Sulkowski is
      Experienced
      . Learn about AIDS Dementia Complex.
      See more AIDS Dementia Complex experts
    • AIDS Dysmorphic Syndrome
      Dr. Sulkowski is
      Experienced
      . Learn about AIDS Dysmorphic Syndrome.
      See more AIDS Dysmorphic Syndrome experts
    • COVID-19
      Dr. Sulkowski is
      Experienced
      . Learn about COVID-19.
      See more COVID-19 experts
    • End-Stage Renal Disease (ESRD)
      Dr. Sulkowski is
      Experienced
      . Learn about End-Stage Renal Disease (ESRD).
      See more End-Stage Renal Disease (ESRD) experts
    • Liver Failure
      Dr. Sulkowski is
      Experienced
      . Learn about Liver Failure.
      See more Liver Failure experts
    • Myelitis
      Dr. Sulkowski is
      Experienced
      . Learn about Myelitis.
      See more Myelitis experts
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.